Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel Free OACC Stock Alerts

Oaktree Acquisition Corp. III Life Sciences (OACC) Competitors

Oaktree Acquisition Corp. III Life Sciences logo
$10.76 +0.01 (+0.09%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

OACC vs. OCSL, GSBD, FSCO, ORC, and BBDC

Should you buy Oaktree Acquisition Corp. III Life Sciences stock or one of its competitors? Oaktree Acquisition Corp. III Life Sciences's main competitors and comparable companies include Oaktree Specialty Lending (OCSL), Goldman Sachs BDC (GSBD), FS Credit Opportunities (FSCO), Orchid Island Capital (ORC), and Barings Bdc (BBDC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does Oaktree Acquisition Corp. III Life Sciences compare to Oaktree Specialty Lending?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and Oaktree Specialty Lending (NASDAQ:OCSL) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Oaktree Specialty Lending has a consensus price target of $11.83, indicating a potential upside of 0.11%. Given Oaktree Specialty Lending's higher probable upside, analysts clearly believe Oaktree Specialty Lending is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oaktree Specialty Lending
1 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.83

Oaktree Specialty Lending has a net margin of 14.45% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Oaktree Specialty Lending's return on equity of 9.70% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
Oaktree Specialty Lending 14.45%9.70%4.64%

36.8% of Oaktree Specialty Lending shares are owned by institutional investors. 0.3% of Oaktree Specialty Lending shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oaktree Specialty Lending has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
Oaktree Specialty Lending$316.80M3.29$33.92M$0.4824.63

In the previous week, Oaktree Specialty Lending had 3 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 4 mentions for Oaktree Specialty Lending and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.79 beat Oaktree Specialty Lending's score of 0.56 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences Very Positive
Oaktree Specialty Lending Positive

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Oaktree Specialty Lending has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Summary

Oaktree Specialty Lending beats Oaktree Acquisition Corp. III Life Sciences on 9 of the 11 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Goldman Sachs BDC?

Goldman Sachs BDC (NYSE:GSBD) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

28.7% of Goldman Sachs BDC shares are held by institutional investors. 0.1% of Goldman Sachs BDC shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Goldman Sachs BDC has a net margin of 17.19% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Goldman Sachs BDC's return on equity of 11.04% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Goldman Sachs BDC17.19% 11.04% 4.62%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

Goldman Sachs BDC has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

In the previous week, Oaktree Acquisition Corp. III Life Sciences had 1 more articles in the media than Goldman Sachs BDC. MarketBeat recorded 1 mentions for Oaktree Acquisition Corp. III Life Sciences and 0 mentions for Goldman Sachs BDC. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.79 beat Goldman Sachs BDC's score of 0.83 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Goldman Sachs BDC Positive
Oaktree Acquisition Corp. III Life Sciences Very Positive

Goldman Sachs BDC presently has a consensus target price of $8.75, indicating a potential downside of 0.65%. Given Goldman Sachs BDC's higher possible upside, equities research analysts clearly believe Goldman Sachs BDC is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Goldman Sachs BDC
3 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
1.86
Oaktree Acquisition Corp. III Life Sciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Goldman Sachs BDC has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Goldman Sachs BDC$365.57M2.71$119.27M$0.5216.94
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Summary

Goldman Sachs BDC beats Oaktree Acquisition Corp. III Life Sciences on 9 of the 12 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to FS Credit Opportunities?

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) and FS Credit Opportunities (NYSE:FSCO) are both small-cap finance companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, FS Credit Opportunities had 1 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 2 mentions for FS Credit Opportunities and 1 mentions for Oaktree Acquisition Corp. III Life Sciences. FS Credit Opportunities' average media sentiment score of 1.81 beat Oaktree Acquisition Corp. III Life Sciences' score of 1.79 indicating that FS Credit Opportunities is being referred to more favorably in the news media.

Company Overall Sentiment
Oaktree Acquisition Corp. III Life Sciences Very Positive
FS Credit Opportunities Very Positive

Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, FS Credit Opportunities has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oaktree Acquisition Corp. III Life Sciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
FS Credit Opportunities
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A
FS Credit Opportunities$137.77M7.32N/AN/AN/A

36.4% of FS Credit Opportunities shares are held by institutional investors. 0.3% of FS Credit Opportunities shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Oaktree Acquisition Corp. III Life SciencesN/A N/A N/A
FS Credit Opportunities N/A N/A N/A

Summary

FS Credit Opportunities beats Oaktree Acquisition Corp. III Life Sciences on 6 of the 7 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Orchid Island Capital?

Orchid Island Capital (NYSE:ORC) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Orchid Island Capital has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchid Island Capital$414M2.43$159.03M$1.483.41
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Orchid Island Capital has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

32.7% of Orchid Island Capital shares are held by institutional investors. 0.3% of Orchid Island Capital shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Orchid Island Capital's return on equity of 11.87% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Orchid Island CapitalN/A 11.87% 1.35%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

In the previous week, Orchid Island Capital and Orchid Island Capital both had 1 articles in the media. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.79 beat Orchid Island Capital's score of -0.09 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Orchid Island Capital Neutral
Oaktree Acquisition Corp. III Life Sciences Very Positive

Orchid Island Capital currently has a consensus price target of $7.50, suggesting a potential upside of 48.66%. Given Orchid Island Capital's higher possible upside, equities research analysts clearly believe Orchid Island Capital is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchid Island Capital
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Oaktree Acquisition Corp. III Life Sciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Orchid Island Capital beats Oaktree Acquisition Corp. III Life Sciences on 7 of the 9 factors compared between the two stocks.

How does Oaktree Acquisition Corp. III Life Sciences compare to Barings Bdc?

Barings Bdc (NYSE:BBDC) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Barings Bdc currently has a consensus target price of $9.75, suggesting a potential upside of 13.70%. Given Barings Bdc's stronger consensus rating and higher probable upside, analysts plainly believe Barings Bdc is more favorable than Oaktree Acquisition Corp. III Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Barings Bdc
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Oaktree Acquisition Corp. III Life Sciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Barings Bdc has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Oaktree Acquisition Corp. III Life Sciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Barings Bdc has higher revenue and earnings than Oaktree Acquisition Corp. III Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Barings Bdc$279.21M3.22$101.92M$0.8310.33
Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A

Barings Bdc has a net margin of 32.73% compared to Oaktree Acquisition Corp. III Life Sciences' net margin of 0.00%. Barings Bdc's return on equity of 10.07% beat Oaktree Acquisition Corp. III Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Barings Bdc32.73% 10.07% 4.38%
Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A

44.1% of Barings Bdc shares are owned by institutional investors. 0.6% of Barings Bdc shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Barings Bdc and Barings Bdc both had 1 articles in the media. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.79 beat Barings Bdc's score of 0.00 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Barings Bdc Neutral
Oaktree Acquisition Corp. III Life Sciences Very Positive

Summary

Barings Bdc beats Oaktree Acquisition Corp. III Life Sciences on 10 of the 11 factors compared between the two stocks.

Get Oaktree Acquisition Corp. III Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for OACC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OACC vs. The Competition

Export
MetricOaktree Acquisition Corp. III Life SciencesCapital Markets IndustryFinance SectorNASDAQ Exchange
Market Cap$264.48M$5.17B$13.50B$13.20B
Dividend YieldN/A7.61%6.07%20.73%
P/E RatioN/A30.0324.7125.83
Price / SalesN/A1,143.67480.05102.96
Price / CashN/A47.6229.5336.12
Price / BookN/A3.472.726.05
Net IncomeN/A$415.07M$1.32B$380.34M
7 Day Performance0.09%-0.49%-0.67%-2.37%
1 Month Performance-0.19%-1.99%-2.68%-4.56%
1 Year Performance1.80%8.78%10.76%-2.00%

Oaktree Acquisition Corp. III Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OACC
Oaktree Acquisition Corp. III Life Sciences
N/A$10.76
+0.1%		N/A+1.7%$264.48MN/AN/A3
OCSL
Oaktree Specialty Lending
2.0959 of 5 stars		$11.91
+0.0%		$11.83
-0.6%		-6.2%$1.05B$316.80M24.80N/A
GSBD
Goldman Sachs BDC
1.9352 of 5 stars		$9.18
+1.2%		$8.75
-4.6%		-8.2%$1.03B$365.57M17.648
FSCO
FS Credit Opportunities
N/A$5.07
-0.9%		N/A-27.6%$1.02B$137.77MN/AN/A
ORC
Orchid Island Capital
2.6884 of 5 stars		$5.11
-0.1%		$7.50
+46.9%		-28.7%$1.02B$414M3.452,018

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OACC) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel